[1]汪尚勇,姜立飞.双歧杆菌乳杆菌三联活菌联合改良序贯疗法治疗Hp阳性慢性萎缩性胃炎的疗效与安全性[J].医学信息,2023,36(24):69-72.[doi:10.3969/j.issn.1006-1959.2023.24.013]
　WANG Shang-yong,JIANG Li-fei.Efficacy and Safety of Live Combined Bifidobacterium and Lactobacillus Combined with Modified Sequential Therapy in the Treatment of Hp Positive Chronic Atrophic Gastritis[J].Journal of Medical Information,2023,36(24):69-72.[doi:10.3969/j.issn.1006-1959.2023.24.013]
点击复制

双歧杆菌乳杆菌三联活菌联合改良序贯疗法治疗Hp阳性慢性萎缩性胃炎的疗效与安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年24期
页码:
69-72
栏目:
论著
出版日期:
2023-12-15

文章信息/Info

Title:
Efficacy and Safety of Live Combined Bifidobacterium and Lactobacillus Combined with Modified Sequential Therapy in the Treatment of Hp Positive Chronic Atrophic Gastritis
文章编号:
1006-1959（2023）24-0069-04
作者:
汪尚勇; 姜立飞
（1.广信区疾病预防控制中心消化内科，江西 上饶 334100；2.广信区中医院消化内科，江西 上饶 334100）
Author(s):
WANG Shang-yong; JIANG Li-fei
(1.Department of Gastroenterology,Guangxin District Center for Disease Control and Prevention,Shangrao 334100,Jiangxi,China;2.Department of Gastroenterology,Guangxi District Traditional Chinese Medicine Hospital,Shangrao 334100,Jiangxi,China)
关键词:
双歧杆菌乳杆菌三联活菌; 改良序贯疗法; 慢性萎缩性胃炎; 炎症因子
Keywords:
Live combined bifidobacterium and lactobacillus; Modified sequential therapy; Chronic atrophic gastritis; Inflammatory factor
分类号:
R573.3+2
DOI:
10.3969/j.issn.1006-1959.2023.24.013
文献标志码:
A
摘要:
目的 研究双歧杆菌乳杆菌三联活菌联合改良序贯疗法治疗Hp阳性慢性萎缩性胃炎的疗效与安全性。方法 选取2021年3月-2022年3月广信区疾病预防控制中心以及广信区中医院诊治的64例Hp阳性慢性萎缩性胃炎为研究对象，采用随机数字表法分为对照组（n=32）和观察组（n=32）。对照组采用改良序贯疗法治疗，观察组在改良序贯疗法基础上给予双歧杆菌乳杆菌三联活菌治疗，比较两组临床疗效、Hp根除率、炎症因子水平[C反应蛋白（CRP）、白细胞介素-6（IL-6）、血清肿瘤坏死因子-α（TNT-α）]、胃功能指标[后血清胃动素（MTL）、胃泌素（GAS）、胃蛋白酶原Ⅰ（PGⅠ）]以及不良反应发生率。结果 观察组治疗总有效率为93.75%，高于对照组的84.38%（P＜0.05）；观察组Hp根除率为90.63%，高于对照组的81.25%（P＜0.05）；两组治疗后CRP、IL-6、TNT-α水平低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后GAS、PGⅠ高于治疗前，MTL低于治疗前，且观察组GAS、PGⅠ高于对照组，MTL低于对照组（P＜0.05）；观察组不良反应发生率为6.25%，低于对照组的21.88%（P＜0.05）。结论 Hp阳性慢性萎缩性胃炎采用双歧杆菌乳杆菌三联活菌联合改良序贯疗法的效果确切，可提升Hp根除率，改善胃功能，抑制炎症因子水平，且不良反应发生率低。
Abstract:
Objective To investigate the efficacy and safety of live combined bifidobacterium and lactobacillus combined with modified sequential therapy in the treatment of Hp positive chronic atrophic gastritis.Methods From March 2021 to March 2022, 64 patients with Hp positive chronic atrophic gastritis diagnosed and treated by Guangxin District Center for Disease Control and Prevention and Guangxi District Traditional Chinese Medicine Hospital were selected as the research objects. They were divided into control group (n=32) and observation group (n=32) by random number table method. The control group was treated with modified sequential therapy, and the observation group was treated with live combined bifidobacterium and lactobacillus on the basis of modified sequential therapy. The clinical efficacy, Hp eradication rate, inflammatory factor levels [C-reactive protein (CRP), interleukin-6 (IL-6), serum tumor necrosis factor-α (TNT-α)], gastric function indicators [serum motilin (MTL), gastrin (GAS), pepsinogen Ⅰ (PGⅠ)] and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.75%, which was higher than 84.38% in the control group (P<0.05). The eradication rate of Hp in the observation group was 90.63%, which was higher than 81.25% in the control group (P<0.05). After treatment, the levels of CRP, IL-6 and TNT-α in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). After treatment, GAS and PGⅠ in the two groups were higher than those before treatment, MTL was lower than that before treatment, and GAS and PGⅠ in the observation group were higher than those in the control group, MTL was lower than that in the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.25%, which was lower than 21.88% in the control group (P<0.05).Conclusion For Patients with Hp positive chronic atrophic gastritis, live combined bifidobacterium and lactobacillus combined with modified sequential therapy is effective, which can improve the eradication rate of Hp, improve gastric function, inhibit the level of inflammatory factors, and the incidence of adverse reactions is low.

参考文献/References:

[1]贺亚妮,安毅,穆亚娟,等.叶酸和替普瑞酮联合三联疗法对老年Hp阳性慢性萎缩性胃炎患者血清G-17、PG及免疫功能的影响[J].解放军医药杂志,2018,30(9):89-92.[2]Lenti MV,Lahner E,Bergamaschi G,et al.Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study[J].J Clin Med,2019,8(11):1992.[3]张曼,高炳霞,齐颖,等.依卡倍特钠联合常规四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎的疗效观察[J].现代消化及介入诊疗,2020,25(1):76-79.[4]张雪莲,李晓辉,何峰,等.VB12、叶酸联合四联疗法治疗HP相关性慢性萎缩性胃炎的疗效及其对相关因子的影响[J].西部医学,2019,31(7):1048-1052.[5]Mezmale L,Isajevs S,Bogdanova I,et al.Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy[J].Asian Pac J Cancer Prev,2019,20(12):3825-3829.[6]石永强,赵向阳,王小平,等.双歧杆菌三联活菌胶囊辅助治疗伴有焦虑抑郁的幽门螺杆菌阳性慢性萎缩性胃炎的临床观察[J].中国药房,2017,28(17):2380-2383.[7]董安山,潘兆宝,吉华青,等.四联疗法联合胃复春在慢性萎缩性胃炎治疗中的效果观察[J].重庆医学,2017,46(9):1257-1258.[8]瞿丛新.双歧杆菌三联活菌胶囊预防乳腺癌患者化疗后肠道菌群失调症的应用研究[J].中国微生态学杂志,2016,28(6):704-706.[9]王剑,陈志涛,周婷婷,等.雷贝拉唑联合氟哌噻吨美利曲辛片治疗慢性萎缩性胃炎患者的疗效及对血清sIL-2R MDA G-17的影响[J].河北医学,2019,25(8):1333-1336.[10]何飞云,叶斌,潘俊娣,等.养胃颗粒治疗慢性萎缩性胃炎癌前病变的疗效[J].江苏医药,2017,43(24):1804-1806,1812.[11]中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.[12]曾娟,戈焰,郭红,等.健脾疏肝活血解毒法联合四联疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎[J].吉林中医药,2017,37(9):907-911.[13]赖国栋.养胃颗粒与克拉霉素三联疗法对慢性胃炎患者幽门螺杆菌感染的临床疗效评价[J].抗感染药学,2018,15(5):884-886.[14]吴成钧,陈春晓.胃泌素、Hp及T细胞联合检测对老年胃炎病情发展及预后[J].黑龙江医药科学,2016,39(1):62-63.[15]李多,王锐,于永强,等.雷贝拉唑、阿莫西林、克拉霉素联合枳术宽中胶囊治疗老年幽门螺杆菌阳性慢性萎缩性胃炎[J].山东医药,2018,58(3):78-80.[16]吴冬,胡旭军,林言.埃索美拉唑联合喹诺酮类抗生素对幽门螺杆菌阳性胃溃疡患者炎症因子的影响[J].中国生化药物杂志,2016,36(11):94-97.[17]廖利春.双岐杆菌四联活菌联合抗HP感染治疗消化性溃疡的疗效及预后的临床分析[J].疾病监测与控制,2017,11(5):363-365.[18]方辉,李学良.慢性萎缩性胃炎患者根除幽门螺杆菌治疗前后红细胞免疫功能的变化[J].临床消化病杂志,2021,33(2):83-86.[19]任玲,陆红,李海燕,等.以高剂量和普通剂量雷贝拉唑为基础的改良二联疗法根除幽门螺杆菌疗效初探[J].中华消化内镜杂志,2018,35(1):60-62.[20]张冰,贾兰芳,张月晓,等.四联疗法联合双歧杆菌四联活菌片根除幽门螺杆菌临床疗效分析[J].临床军医杂志,2017,45(7):712-714.

相似文献/References:

[1]郑继荣.枯草杆菌二联活菌肠溶胶囊联合改良序贯疗法治疗胃肠炎的疗效与安全性[J].医学信息,2023,36(23):111.[doi:10.3969/j.issn.1006-1959.2023.23.028]
　ZHENG Ji-rong.Efficacy and Safety of Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules Combined with Modified Sequential Therapy in the Treatment of Gastroenteritis[J].Journal of Medical Information,2023,36(24):111.[doi:10.3969/j.issn.1006-1959.2023.23.028]

更新日期/Last Update: 1900-01-01